Summit Therapeutics Inc. (SMMT)
Nasdaq · Healthcare · Biotechnology
$17.27+3.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $13.8B
- 52-week range
- $12.07 – $29.23
- 52-week change
- −24.83%
- EPS (trailing)
- −$1.11
- Analyst rating
- 1.8 Buy
- Next earnings
- Oct 19, 2026
Fiscal year to Dec 2025
- Net income
- −$1.1B
- Diluted EPS
- −$1.44
- Free cash flow
- −$324M
From the company’s annual report on SEC EDGAR.
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Headquarters: Miami, United States · 265 employees · smmttx.com